Currently, under- or over-diagnosis of cardiovascular disease sometimes
results in failure to prevent adverse events or inappropriate
interruption of a potentially life-saving anticancer treatment. "We need
to be clear when it's a must to stop the treatment, when we should
reduce the dose, or when we can continue with the therapy," said
Professor Zamorano. "This position paper provides guidance in this
area."
0
comments
:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.